Biotechnology company
Appears in 1 story · Last updated Nov 10, 2026
Co-developer and platform owner
BioNTech and DualityBio's Phase 3 breast cancer trial met its main goal, but the result is muted. Trastuzumab pamirtecan delayed tumor growth longer than chemotherapy in 541 patients with hormone receptor-positive, HER2-low metastatic breast cancer, a gain the companies call "statistically significant, yet modest."
Updated Yesterday
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
